En­ta­sis lands first an­tibi­ot­ic ap­proval eight years af­ter spin­ning out of As­traZeneca

Al­most eight years af­ter spin­ning out As­traZeneca’s an­tibi­otics pipeline, En­ta­sis Ther­a­peu­tics has land­ed its first ap­proval.

The FDA ap­proved its Xac­duro, made up of sul­bac­tam …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER